Head-To-Head Analysis: Ryman Healthcare (OTCMKTS:RYHTY) vs. Organon & Co. (NYSE:OGN)

Ryman Healthcare (OTCMKTS:RYHTYGet Free Report) and Organon & Co. (NYSE:OGNGet Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Volatility & Risk

Ryman Healthcare has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Earnings and Valuation

This table compares Ryman Healthcare and Organon & Co.”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ryman Healthcare $502.59 million 2.47 -$100.65 million N/A N/A
Organon & Co. $6.16 billion 0.58 $187.00 million $0.93 14.52

Organon & Co. has higher revenue and earnings than Ryman Healthcare.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ryman Healthcare and Organon & Co., as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ryman Healthcare 0 0 0 0 0.00
Organon & Co. 2 5 0 0 1.71

Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.59%. Given Organon & Co.’s stronger consensus rating and higher probable upside, analysts plainly believe Organon & Co. is more favorable than Ryman Healthcare.

Institutional & Insider Ownership

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ryman Healthcare and Organon & Co.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ryman Healthcare N/A N/A N/A
Organon & Co. 3.99% 99.95% 6.22%

Summary

Organon & Co. beats Ryman Healthcare on 10 of the 11 factors compared between the two stocks.

About Ryman Healthcare

(Get Free Report)

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The company's villages provide a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which offers rest homes, hospitals, dementia-level care, and respite and day care services. Its villages also provide all-weather bowling green, indoor heated swimming pool and spa, gym, internal atrium, beauty and hair salons, library, dining area, bar, lounges, croquet laws, shops, and movie theatre facilities. The company owns and operates retirement village units and care units. The company was founded in 1984 and is based in Christchurch, New Zealand.

About Organon & Co.

(Get Free Report)

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Receive News & Ratings for Ryman Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryman Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.